靶向肺去神经支配术治疗慢性阻塞性肺疾病的研究进展  

Research progress of targeted lung denervation in the treatment of chronic obstructive pulmonary disease

作　　者：熊力 张先明 Xiong Li;Zhang Xianming(Department of Respiratory and Critical Care Medicine,the Affiliated Hospital of Guizhou Medical University,Guiyang 550004,China)

机构地区：[1]贵州医科大学附属医院呼吸与危重症医学科,贵阳550004

出　　处：《中国医师杂志》2025年第2期313-317,共5页Journal of Chinese Physician

摘　　要：慢性阻塞性肺疾病(COPD)的特点是不完全可逆的气流阻塞、持续性气道炎症以及系统性并发症。吸烟是COPD发病的主要诱因,同时遗传因素、肺部发育和环境刺激在COPD的病理生物学过程中发挥作用。治疗COPD的主要药物是支气管扩张剂,包括β2激动剂和长效抗胆碱能药物(通常与吸入性皮质类固醇联合使用)。然而,近年来的研究和临床治疗表明,即使在最佳药物治疗下,仍存在COPD频繁加重的问题。因此,探索新的治疗方法和技术至关重要。靶向肺去神经支配术(TLD)是一种新兴内镜治疗方法,本文对TLD治疗COPD的作用机制、操作流程及临床应用效果作一综述。Chronic obstructive pulmonary disease(COPD)is characterized by incomplete reversible airflow obstruction,persistent airway inflammation,and systemic complications.Smoking is the main cause of COPD,while genetic factors,lung development and environmental stimuli play a role in the pathobiological process of COPD.The main drugs used to treat COPD are bronchodilators,including beta-2 agonists and long-acting anticholinergics(often used in combination with inhaled corticosteroids).However,research and clinical treatment in recent years have shown that frequent exacerbations of COPD exist even with the best medical treatment.Therefore,it is crucial to explore new treatments and technologies.Targeted lung denervation(TLD)is a new endoscopic therapy.This article reviews the mechanism of action,procedure and clinical application of TLD in COPD.

关 键 词：肺疾病 慢性阻塞性 靶向肺去神经支配术 

分 类 号：R56[医药卫生—呼吸系统]